Novo Nordisk faces investor lawsuit over 'false and misleading' semaglutide sales projections

Novo Nordisk faces an investor class-action lawsuit alleging "false and misleading statements" regarding competition from compounded GLP-1 drugs, filed after the company significantly cut its 2025 sales growth forecast from 13-21% to 8-14% and operating profit growth from 20% to 13%. This guidance revision, which Novo attributed to persistent compounded drug use and heightened competition from Eli Lilly, triggered a 22% stock decline. The lawsuit, covering shares purchased between May 7 and July 28, seeks to recover investor losses, as Novo's Q1 Wegovy and Ozempic sales already showed sequential declines while Lilly's competing drugs demonstrated growth.

Analysis

Novo Nordisk is confronting a multi-faceted crisis, underscored by a significant 22% share price decline following a severe reduction in its 2025 financial guidance. The company slashed its sales growth forecast from a 13-21% range to 8-14% and cut its operating profit growth midpoint from 20% to 13%, signaling a material deterioration in its outlook. This revision is attributed to two primary competitive pressures that the company appears to have previously underestimated: the persistent market presence of cheaper, compounded GLP-1 drugs and intensifying competition from Eli Lilly. The impact of this competition is already evident in Novo's first-quarter results, where Wegovy and Ozempic sales saw sequential declines of 13% and 3%, respectively. In stark contrast, Eli Lilly's competing drugs, Zepbound and Mounjaro, posted sequential growth of 21% and 9% in the same period, indicating a clear market share shift. Compounding these operational challenges is a new class-action lawsuit alleging that Novo Nordisk made "false and misleading statements" by downplaying these competitive threats to investors between May 7 and July 28, creating a significant legal and reputational overhang.

Key Decisions for Investors

• Given the significant guidance reduction, mounting legal risk from the class-action lawsuit, and evidence of market share erosion, investors should exercise extreme caution and reassess the premium valuation of Novo Nordisk.
• Monitor Novo Nordisk's upcoming second-quarter earnings report closely for the magnitude of sales deceleration in Wegovy and Ozempic and for management's updated strategy to counter compounded drugs and Eli Lilly.
• The contrasting growth trajectories suggest Eli Lilly is a primary beneficiary of Novo's challenges, warranting consideration of a potential pairs trade (long LLY, short NVO) or a portfolio reallocation toward Lilly within the GLP-1 therapeutic space.
• The pending litigation represents a material, unquantified risk that should be factored into valuation models, as a negative outcome could result in significant financial penalties and further damage investor confidence.